Brief: Anteris Technologies Says US FDA Approves Early Feasibility Study For Duravr
28/11/2022 01:30
Nov 28 (Reuters) - Anteris Technologies Ltd AVR.AX :
* US FDA APPROVES EARLY FEASIBILITY STUDY FOR DURAVR THV
SYSTEM
Source text for Eikon: ID:nASXYsG4F
Further company coverage: AVR.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anteris Technologies
See all newsBrief: Anteris Technologies Global Corp Gets French Regulatory Clearance For Duravr Paradigm Global Pivotal Trial
Anteris Technologies up as brokerages initiate coverage post-research quiet period
Brief: Anteris Technologies Says Aggregate Gross Proceeds From Offering Was $88.8 Mln
Anteris Technologies slides in Nasdaq debut after $89 mln US IPO
Brief: Anteris Technologies Prices 14.8 Mln Shares At $6.00 Per Share for U.S. IPO